LENZ Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

	Stockholders' Equity
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity
Shares · Amount
Balance as of December 31, 2025	31,344,782		$1		$511,237		$(227,141)		$242		$284,339
Exercise of stock options	2,698	—		14		—		—		14
Unrealized loss on marketable securities	—	—		—		—		(692)		(692)
Vesting of restricted stock units	6,914	—		—		—		—		—
Share-based compensation	—	—		4,319		—		—		4,319
Net loss	—	—		—		(41,488)		—		(41,488)
Balance as of March 31, 2026	31,354,394		$1		$515,570		$(268,629)		$(450)		$246,492
Unrealized loss on marketable securities	—	—		—		—		(179)		(179)
Share-based compensation	—	—		4,472		—		—		4,472
Issuance of common stock under employee stock purchase plan	62,498	—		395		—		—		395
Net loss	—	—		—		(31,918)		—		(31,918)
Balance as of June 30, 2026	31,416,892		$1		$520,437		$(300,547)		$(629)		$219,262
Exercise of stock options	240		—		—		—		—		-
Unrealized loss on marketable securities	—		—		—		—		(428)		(428)
Vesting of restricted stock units	3,451		—		—		—		—		-
Share-based compensation	—		—		4,134		—		—		4,134
Net loss	—		—		—		(30,969)		—		(30,969)
Balance as of September 30, 2026	31,420,583	$1		$524,571		$(331,516)		$(1,057)		$191,999

	Stockholders' Equity
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity
Shares · Amount
Balance as of December 31, 2024	27,518,439	$1		$348,901		$(145,014)		$196		$204,084
Exercise of stock options	11,630	—		44		—		—		44
Unrealized loss on marketable securities	—	—		—		—		(73)		(73)
Vesting of early exercised stock options	5,594	—		19		—		—		19
Share-based compensation	—	—		2,555		—		—		2,555
Net loss	—	—		—		(14,619)		—		(14,619)
Balance as of March 31, 2025	27,535,663		$1		$351,519		$(159,633)		$123		$192,010
Exercise of stock options	29,003	—		196		—		—		196
Unrealized loss on marketable securities	—	—		—		—		(85)		(85)
Vesting of early exercised stock options	5,593	—		19		—		—		19
Share-based compensation	—	—		2,845		—		—		2,845

Issuance of common stock through at-the-market offerings, net of issuance costs	920,500	—		26,067		—		—		26,067
Exercise of stock warrant	271	—		—		—		—		—
Issuance of common stock under employee stock purchase plan	9,092	—		225		—		—		225
Net loss	—	—		—		(14,912)		—		(14,912)
Balance as of June 30, 2025	28,500,122		$1		$380,871		$(174,545)		$38		$206,365
Exercise of stock options	86,275		—		598		—		—		598
Unrealized gain on marketable securities	—		—		—		—		189		189
Vesting of early exercised stock options	1,864		—		6		—		—		6
Share-based compensation	—		—		3,469		—		—		3,469
Net loss	—		—		—		(16,700)		—		(16,700)
Balance as of September 30, 2025	28,588,261	$1		$384,944		$(191,245)		$227		$193,927

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.